CNBC September 8, 2024
Key Points
– Leqembi, an Alzheimer’s drug from Biogen and Eisai, could give patients at the earliest stages of the disease more time to live normally and independent of others.
– But patients face a long road to treatment due to the new and complicated system associated with taking the drug.
– There are bottlenecks related to reimbursement uncertainties, diagnostic test requirements, the need for regular brain scans and difficulties finding neurologists.
Leqembi, an Alzheimer’s drug from Biogen and Eisai, isn’t a cure for the mind-damaging disease.
But the treatment promises to give patients such as Missie Meeks more time to live their daily lives normally and independently of others.
Meeks, an English professor based in Ellisville, Mississippi, was...
Today's Sponsors
Today's Sponsor